Resource Summary Report

Generated by NIF on Aug 2, 2026

D425 Med

RRID:CVCL_1275
Type: Cell Line

Proper Citation

RRID:CVCL_1275

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1275

Proper Citation: RRID:CVCL_1275

Description: Cell line D425 Med is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Medulloblastoma, non-WNT/non-SHH, group 3

Defining Citation: PMID:1822845, PMID:1904513, PMID:2180567, PMID:11916498, PMID:20847082, PMID:21177782, PMID:21667264, PMID:22343310, PMID:24297863, PMID:24300787, PMID:27498314, PMID:27812533

Comments: Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: D425 Med

Synonyms: D-425 Med, D-425 Med-C, D-425MED, D425_Med, D425MED, D425Med, Med 425, D-425, D425, H425

Cross References: BioGRID_ORCS_Cell_line:1665, cancercelllines:CVCL_1275, Cell_Model_Passport:SIDM01501, Cosmic:973264, Cosmic:2362651, Cosmic:2772985, DepMap:ACH-001053, GEO:GSM482334, GEO:GSM919359, Lonza:1683, Millipore:SCC290, Progenetix:CVCL_1275, Wikidata:Q54817229

ID: CVCL_1275

Record Creation Time: 20220427T215609+0000

Record Last Update: 20260801T235655+0000

Ratings and Alerts

No rating or validation information has been found for D425 Med.

No alerts have been found for D425 Med.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Richman CM, et al. (2025) Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy. Cancer research, 85(19), 3737.

Dang D, et al. (2025) Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis. Cancer cell, 43(6), 1159.

Hofman DA, et al. (2024) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. Molecular cell, 84(2), 261.

Veo B, et al. (2024) Single-cell multi-omics analysis identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma. Research square.

Zeuner S, et al. (2024) Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells. Journal of neuro-oncology, 166(1), 99.

Katsushima K, et al. (2024) A therapeutically targetable positive feedback loop between lnc-HLX-2-7, HLX, and MYC that promotes group 3 medulloblastoma. Cell reports, 43(3), 113938.

Ampudia-Mesias E, et al. (2024) The OTX2 Gene Induces Tumor Growth and Triggers Leptomeningeal Metastasis by Regulating the mTORC2 Signaling Pathway in Group 3 Medulloblastomas. International journal of molecular sciences, 25(8).

Lukoseviciute M, et al. (2023) Combination of PARP and WEE1 inhibitors in??vitro: Potential for use in the treatment of SHH medulloblastoma. Oncology reports, 49(6).

Hofman DA, et al. (2023) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. bioRxiv : the preprint server for

biology.

Bakhshinyan D, et al. (2023) Dynamic profiling of medulloblastoma surfaceome. Acta neuropathologica communications, 11(1), 111.

Mondal I, et al. (2023) PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma. Cancer research, 83(15), 2527.

Vollmer J, et al. (2023) Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells. Journal of neuro-oncology, 164(3), 617.

Chen Z, et al. (2022) Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation. Cell death and differentiation, 29(10), 1955.

Veo B, et al. (2021) Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma. Cell reports, 35(4), 109013.